Cargando…

Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up

BACKGROUND: Refractory/relapsed angioimmunoblastic T cell lymphoma (AITL) with Evans syndrome is a very rare condition with a poor prognosis. There is no evidence-based treatment strategy for refractory/relapsed AITL with Evans syndrome. CASE PRESENTATION: A 51-year-old female was admitted to our ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Fang, Li, Qiuhui, Pan, Huaxiong, Xiao, Yin, Liu, Tao, Liu, Xinxiu, Li, Juan, Wu, Gang, Zhang, Liling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481371/ https://www.ncbi.nlm.nih.gov/pubmed/32984055 http://dx.doi.org/10.3389/fonc.2020.01725

Ejemplares similares

Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review
por: Jin, Jingxia, et al.
Publicado: (2018)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Liu, Weiping, et al.
Publicado: (2021)

Diagnosis and Treatment of Synchronous Lymphoma and Digestive System Carcinoma: Report of Four Cases and Literature Review
por: Meng, Jingshu, et al.
Publicado: (2019)

Therapeutic Effect of CAOLD Chemotherapy Regimen on Patients With Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: A Case Study
por: Liu, Yu, et al.
Publicado: (2022)

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
por: Laribi, Kamel, et al.
Publicado: (2022)

A Primary Mediastinal Large B-Cell Lymphoma Patient With COVID-19 Infection After Intensive Immunochemotherapy: A Case Report
por: Li, Qiuhui, et al.
Publicado: (2020)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

Primary central nervous system lymphoma after heart transplantation: A case report and literature review
por: Zhu, Fang, et al.
Publicado: (2020)

A case report of primary prostate intravascular large B cell lymphoma presenting as prostatic hyperplasia
por: Zhu, Fang, et al.
Publicado: (2019)

Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial
por: Wang, Yawen, et al.
Publicado: (2022)

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
por: Zeng, Qiang, et al.
Publicado: (2023)

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma
por: Pro, Barbara, et al.
Publicado: (2016)

Identification of hub genes and key pathways associated with angioimmunoblastic T-cell lymphoma using weighted gene co-expression network analysis
por: Li, Xiaoqian, et al.
Publicado: (2019)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Long-term outcomes of upfront concurrent chemoradiotherapy followed by P-GDP regimen in newly diagnosed early stage extranodal nasal-type NK/T cell lymphoma: A prospective single-center phase II study
por: Zhu, Fang, et al.
Publicado: (2020)

Invasive Aspergillosis in Refractory Angioimmunoblastic T-Cell Lymphoma
por: NP, Prakash, et al.
Publicado: (2018)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen
por: Chen, Xing-Gui, et al.
Publicado: (2011)

Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review
por: Chen, Chao, et al.
Publicado: (2021)

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma
por: Xue, Kai, et al.
Publicado: (2021)

Case Report: Long-Term Response to Radiotherapy Combined With Targeted Therapy in Histiocytic Sarcoma Harboring Mutations in MAPK and PI3K/AKT Pathways
por: Liu, Zijian, et al.
Publicado: (2021)

Effectiveness of cyclosporine and mycophenolate mofetil in a child with refractory evans syndrome
por: Farruggia, Piero, et al.
Publicado: (2011)

Case Report: Outcome and Adverse Events of Anti-PD-1 Antibody Plus Chidamide for Relapsed/Refractory Sézary Syndrome: Case Series and A Literature Review
por: Chen, Chao, et al.
Publicado: (2022)

Relapsed Angioimmunoblastic T Cell Lymphoma with Fulminant Leukemic Involvement
por: Altahan, Rahaf, et al.
Publicado: (2022)

Relapsed angioimmunoblastic T-cell lymphoma presenting as psoriasiform dermatitis
por: McClure, Spencer, et al.
Publicado: (2023)

Successful treatment of angioimmunoblastic T-cell lymphoma with clarithromycin
por: Ohe, Masashi, et al.
Publicado: (2016)

Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

Synchronous double primary lymphoma and thyroid cancer: A single-institution retrospective study
por: Li, Qiuhui, et al.
Publicado: (2021)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

Treatment selection for patients with relapsed or refractory follicular lymphoma
por: Skarbnik, Alan Z., et al.
Publicado: (2023)

S238: CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY
por: Loyaux, Romain, et al.
Publicado: (2023)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
por: Zhang, Yujie, et al.
Publicado: (2022)

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
por: Yan, Zheng, et al.
Publicado: (2020)

P1133: CHIDAMIDE PLUS PREDNISONE, CYCLOPHOSPHAMIDE, AND THALIDOMIDE (CPCT) FOR RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER PHASE II TRIAL
por: Liang, Jinhua, et al.
Publicado: (2023)

A new prognostic nomogram in patients with mucosa-associated lymphoid tissue lymphoma: a multicenter retrospective study
por: Wen, Qiuyue, et al.
Publicado: (2023)

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases
por: Du, Lijun, et al.
Publicado: (2020)

Chidamide in the treatment of peripheral T-cell lymphoma
por: Chan, Thomas S, et al.
Publicado: (2017)

Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study
por: Chen, Xinrui, et al.
Publicado: (2021)

Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study
por: Liu, Tao, et al.
Publicado: (2018)

A preliminary investigation of the relationship between (18)F-FDG PET/CT metabolic parameters and prognosis in angioimmunoblastic T-cell lymphoma
por: Hu, Lanping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cana426g4ed9dpk5c0bp01o133